» Articles » PMID: 11705103

Ibogaine: a Review

Overview
Specialties Biology
Chemistry
Date 2001 Nov 14
PMID 11705103
Citations 42
Authors
Affiliations
Soon will be listed here.
Citing Articles

Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.

Chen D, Inzunza Dominguez J, Valle Uzeta J, Pushparaj A, Dickinson J Front Immunol. 2025; 16:1535782.

PMID: 39981248 PMC: 11839422. DOI: 10.3389/fimmu.2025.1535782.


Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models.

Havel V, Kruegel A, Bechand B, McIntosh S, Stallings L, Hodges A Nat Commun. 2024; 15(1):8118.

PMID: 39304653 PMC: 11415492. DOI: 10.1038/s41467-024-51856-y.


Ibogaine administration following repeated morphine administration upregulates myelination markers 2', 3'-cyclic nucleotide 3'-phosphodiesterase (CNP) and myelin basic protein (MBP) mRNA and protein expression in the internal capsule of Sprague....

Govender D, Moloko L, Papathanasopoulos M, Tumba N, Owen G, Calvey T Front Neurosci. 2024; 18:1378841.

PMID: 39114487 PMC: 11303312. DOI: 10.3389/fnins.2024.1378841.


Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.

Gomez-Escolar A, Folch-Sanchez D, Stefaniuk J, Swithenbank Z, Nisa A, Braddick F CNS Drugs. 2024; 38(10):771-789.

PMID: 39033264 DOI: 10.1007/s40263-024-01101-3.


Ibogaine Induces Cardiotoxic Necrosis in Rats-The Role of Redox Processes.

Vidonja Uzelac T, Tatalovic N, Mijovic M, Miler M, Grahovac T, Orescanin Dusic Z Int J Mol Sci. 2024; 25(12).

PMID: 38928231 PMC: 11203496. DOI: 10.3390/ijms25126527.